Safety and Effectiveness of Canakinumab for Schnitzler's Syndrome
Part of Immune system & allergy clinical trials.
This study tracks how well and safely canakinumab (a medication that reduces inflammation) works in patients newly diagnosed with Schnitzler's syndrome. Schnitzler's syndrome is a rare condition causing recurring fevers, rashes, and joint pain, and this study helps doctors understand how this drug performs in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Schnitzler's syndrome
- You are starting canakinumab for the first time for Schnitzler's syndrome
- You have not previously participated in a specific earlier study called IACT21071
- You are not taking canakinumab for any other inflammatory condition (such as familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or Still's disease)
- You are not receiving canakinumab as part of a patient-initiated or investigator-initiated trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry, meaning it collects your medical information to better understand several inflammatory (auto-inflammatory) conditions. It may help doctors and researchers improve diagnosis and future treatments for people with these disorders.
This is a study looking back at patients who were already treated with a medicine called canakinumab for familial Mediterranean fever or Still's disease (rare conditions that cause fevers and joint pain). Researchers want to understand how well this medicine worked over time and what happened to patients who took it.
This Phase 4 study tests how an anti-inflammatory approach affects people with schizophrenia or schizoaffective disorder who also have signs of body inflammation. It may help by targeting inflammation that could be linked to symptoms for some people.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
This study tests an investigational drug called KSVCBD for people with certain autoimmune diseases that haven't improved with standard treatments. It aims to see if the drug is safe and if it can help reduce symptoms.
This study tests whether clazakizumab can reduce the risk of heart attacks or strokes in people with high levels of inflammation (measured by a blood test called hsCRP) and conditions like heart disease, obesity, diabetes, high blood pressure, or kidney disease. If you qualify, you'll receive either the study drug or a placebo to see if it helps lower your risk.
Hear when a new Schnitzler Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.